Novo Nordisk Shares Drop Significantly Amid Sales and Profit Warnings
TL;DR
Novo Nordisk has lowered its sales forecast for the obesity drug Wegovy due to increased competition from compounded versions made by pharmacies, which are not FDA-approved but are legally customized for individual patients. The company is taking legal action to address this issue and has announced a new CEO, Maziar Mike Doustdar. Despite efforts to sell Wegovy directly to consumers, sales through cash channels have been lower than expected, impacting the company's stock.
Topics:top-newsbusiness#business#compounding-pharmacies#novo-nordisk#obesity-drug#sales-forecast#wegovy
- Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding NPR
- Novo Nordisk Shares Plummet as Competition Weighs on Sales The Wall Street Journal
- Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning The New York Times
- Novo Nordisk shares plunge 23% after Wegovy maker names new CEO, cuts full-year guidance CNBC
- Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition Yahoo Finance
Want the full story? Read the original reporting
Read on NPR